The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vupparapalli Parvani
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vupparapalli Pavani, a member of the promoter group of Novelix Pharmaceuticals Ltd (formerly Trimurthi Limited), was allotted 3,25,000 equity shares (1.63% of share capital) through a preferential allotment on 12 February 2026. Her holding increased from 4,00,000 shares (2.27%) to 7,25,000 shares (3.64% of total share capital, or 2.66% on a diluted basis). The company's total equity share capital rose from Rs. 17.62 crore (1.76 crore shares) to Rs. 19.94 crore (1.99 crore shares) as a result of this preferential issue. The diluted share capital stands at Rs. 26.69 crore, including 73,35,000 outstanding convertible warrants. The disclosure was filed under Regulation 29(2) of SEBI (SAST) Regulations, 2011.
The promoter group has increased its stake through preferential allotment, which generally signals insider confidence in the company. However, this also means dilution for existing public shareholders, and the promoter's post-allotment holding is still modest at 3.64%, far below the 5% creeping acquisition threshold.